ATE501267T1 - Apolipoprotein-a-ii-isoform als biomarker für prostatakrebs - Google Patents

Apolipoprotein-a-ii-isoform als biomarker für prostatakrebs

Info

Publication number
ATE501267T1
ATE501267T1 AT06717624T AT06717624T ATE501267T1 AT E501267 T1 ATE501267 T1 AT E501267T1 AT 06717624 T AT06717624 T AT 06717624T AT 06717624 T AT06717624 T AT 06717624T AT E501267 T1 ATE501267 T1 AT E501267T1
Authority
AT
Austria
Prior art keywords
biomarker
prostate cancer
isoform
useful
apolipoprotein
Prior art date
Application number
AT06717624T
Other languages
English (en)
Inventor
John Semmes
Gunjan Malik
Michael Ward
Original Assignee
Eastern Virginia Med School
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eastern Virginia Med School filed Critical Eastern Virginia Med School
Application granted granted Critical
Publication of ATE501267T1 publication Critical patent/ATE501267T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
AT06717624T 2005-01-06 2006-01-06 Apolipoprotein-a-ii-isoform als biomarker für prostatakrebs ATE501267T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64233205P 2005-01-06 2005-01-06
PCT/US2006/000450 WO2006074360A2 (en) 2005-01-06 2006-01-06 Apolipoprotein a-ii isoform as a biomarker for prostate cancer

Publications (1)

Publication Number Publication Date
ATE501267T1 true ATE501267T1 (de) 2011-03-15

Family

ID=36648206

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06717624T ATE501267T1 (de) 2005-01-06 2006-01-06 Apolipoprotein-a-ii-isoform als biomarker für prostatakrebs

Country Status (8)

Country Link
US (1) US7811772B2 (de)
EP (1) EP1838867B1 (de)
JP (1) JP2008527351A (de)
AT (1) ATE501267T1 (de)
AU (1) AU2006203948A1 (de)
CA (1) CA2593184A1 (de)
DE (1) DE602006020544D1 (de)
WO (1) WO2006074360A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7618788B2 (en) * 2002-05-10 2009-11-17 Millipore Corporation Proteome epitope tags and methods of use thereof in protein modification analysis
US7855057B2 (en) * 2006-03-23 2010-12-21 Millipore Corporation Protein splice variant/isoform discrimination and quantitative measurements thereof
FR2919062B1 (fr) 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'aminoacylase 1 pour le diagnostic in vitro du cancer colorectal.
FR2919061B1 (fr) 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de la plastine-i pour le diagnostic in vitro du cancer colorectal.
FR2919060B1 (fr) 2007-07-19 2012-11-30 Biomerieux Sa Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal.
FR2919064B1 (fr) * 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'apolipoproteine all pour le diagnostic in vitro du cancer colorectal
US9726670B2 (en) 2007-07-19 2017-08-08 Biomerieux Method for the assay of liver fatty acid binding protein, ACE and CA 19-9 for the in vitro diagnosis of colorectal cancer
FR2919065B1 (fr) 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'apolipoproteine ai pour le diagnostic in vitro du cancer colorectal
FR2919063B1 (fr) 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage du leucocyte elastase inhibitor pour le diagnostic in vitro du cancer colorectal.
EP2250508A1 (de) * 2008-02-07 2010-11-17 Hadasit Medical Research Services & Development Limited Immundetektion eines karzinösen zustandes bei einer person
FR2933773B1 (fr) 2008-07-10 2013-02-15 Biomerieux Sa Procede de dosage de la proteine disulfide isomerase pour le diagnostic in vitro du cancer colorectal
US20150160224A1 (en) * 2012-04-27 2015-06-11 Eastern Virginia Medical School Quantitation of biomarkers for the detection of prostate cancer
US20150133342A1 (en) * 2012-05-04 2015-05-14 Nuclea Biotechnologies, Inc. Mrm-ms signature assay
JP2014021083A (ja) * 2012-07-24 2014-02-03 Hitachi High-Technologies Corp 質量分析方法及び質量分析システム
CA3210007A1 (en) * 2013-03-15 2014-09-18 Sera Prognostics, Inc Biomarkers and methods for predicting preeclampsia
DK3054298T3 (en) * 2013-10-01 2019-04-08 Toray Industries METHOD OF DETECTING TUMOR IN THE ARC
WO2016054031A1 (en) 2014-10-02 2016-04-07 Biodesix, Inc. Predictive test for aggressiveness or indolence of prostate cancer from mass spectrometry of blood-based sample
CN104503429B (zh) * 2014-11-26 2017-06-06 中车青岛四方机车车辆股份有限公司 轨道交通车辆静态试验数据自动化处理方法及装置
EP3252474B1 (de) * 2015-01-26 2020-10-21 Toray Industries, Inc. Verfahren und kit zur detektion von gallengangkrebs
DK3267197T3 (da) * 2015-03-02 2020-10-12 Toray Industries Fremgangsmåde og kit til detektionen af pankreatisk dysfunktion
PL3311158T3 (pl) 2015-06-19 2023-11-27 Sera Prognostics, Inc. Pary biomarkerów do przewidywania przedwczesnego porodu
EP3668996A4 (de) 2017-08-18 2021-04-21 Sera Prognostics, Inc. Clock-schwangerschaftsprotein zur vorhersage des entbindungstermins und der zeit bis zur entbindung
US11681953B2 (en) 2018-04-13 2023-06-20 Freenome Holdings, Inc. Machine learning implementation for multi-analyte assay development and testing

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE462454B (sv) * 1988-11-10 1990-06-25 Pharmacia Ab Maetyta foer anvaendning i biosensorer
US5512657A (en) * 1988-12-12 1996-04-30 Bainbridge Sciences, Inc. Detection of complexes which include basement membrane components as diagnostic of cancer and other diseases
DE4023945A1 (de) * 1990-07-27 1992-01-30 Progen Biotechnik Gmbh Verfahren zur reinigung von cytokeratin 20 und dessen verwendung zur erzeugung von antikoerpern
WO1993024834A1 (en) 1992-05-29 1993-12-09 The Rockefeller University Method and product for the sequence determination of peptides using a mass spectrometer
US6283761B1 (en) * 1992-09-08 2001-09-04 Raymond Anthony Joao Apparatus and method for processing and/or for providing healthcare information and/or healthcare-related information
US6020208A (en) * 1994-05-27 2000-02-01 Baylor College Of Medicine Systems for surface-enhanced affinity capture for desorption and detection of analytes
EP1347493A3 (de) * 1993-05-28 2005-11-23 Baylor College Of Medicine Verfahren und Gerät zur Desorption und Ionisierung von Analyte
NZ516848A (en) * 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
AU3463699A (en) 1998-04-03 1999-10-25 Phylos, Inc. Addressable protein arrays
US6406921B1 (en) * 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
GB9821170D0 (en) 1998-09-30 1998-11-25 Univ Ulster Marker
WO2000029987A1 (en) 1998-11-17 2000-05-25 University Of Maryland Methods for identifying and classifying organisms by mass spectrometry and database searching
AU4025300A (en) 1999-03-24 2000-10-09 Packard Bioscience Company Continuous porous matrix arrays
DE60045816D1 (de) 1999-04-27 2011-05-19 Bio Rad Laboratories Probenhalter für ein gasphaseionenspektrometer
CN1169188C (zh) * 1999-04-29 2004-09-29 赛弗根生物系统股份有限公司 具有憎水覆层的气相质谱仪样品支架
US6482599B1 (en) * 1999-04-30 2002-11-19 Hybritech Incorporated Forms of prostate specific antigen (PSA) specific for benign prostatic hyperplasia (BPH) and methods of using such
JP5064625B2 (ja) 1999-10-27 2012-10-31 バイオウルフ テクノロジーズ エルエルスィー パターンを同定するための方法及び機械
US6936424B1 (en) 1999-11-16 2005-08-30 Matritech, Inc. Materials and methods for detection and treatment of breast cancer
DE60127104D1 (de) 2000-03-20 2007-04-19 Eastern Virginia Med School Prostatakrebs-marker
CN1276255C (zh) 2000-07-13 2006-09-20 希森美康株式会社 肾病检查试剂以及检查肾病及其组分的方法
MXPA03000506A (es) * 2000-07-18 2004-09-10 Correlogic Systems Inc Proceso para discriminiar entre estados biologicos basados en patrones escondidos de datos biologicos.
AU2002220265A1 (en) * 2000-11-03 2002-05-15 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
CA2429327A1 (en) 2000-11-16 2003-04-17 Ciphergen Biosystems, Inc. Method for analyzing mass spectra
AU2002255525B2 (en) * 2001-02-09 2007-01-04 Pintex Pharmaceuticals, Inc. Pin1 as a marker for prostate cancer
US7113896B2 (en) * 2001-05-11 2006-09-26 Zhen Zhang System and methods for processing biological expression data
AU2002367582A1 (en) * 2001-07-17 2003-09-29 Ciphergen Biosystems, Inc. Latex based adsorbent chip
US7842498B2 (en) 2001-11-08 2010-11-30 Bio-Rad Laboratories, Inc. Hydrophobic surface chip
US20040018519A1 (en) * 2001-11-16 2004-01-29 Wright ,Jr. George L Methods and devices for quantitative detection of prostate specific membrane antigen and other prostatic markers
US20030207462A1 (en) * 2002-01-25 2003-11-06 Ciphergen Biosystems, Inc. Monomers and polymers having energy absorbing moieties of use in desorption/ionization of analytes
US7704700B2 (en) * 2002-02-12 2010-04-27 Burnham Institute For Medical Research Methods for determining the prognosis for patients with a prostate neoplastic condition using inhibitor of apoptosis polypeptides
US20020193950A1 (en) * 2002-02-25 2002-12-19 Gavin Edward J. Method for analyzing mass spectra
AU2003231084A1 (en) 2002-04-26 2003-11-10 The Johns Hopkins University Identification of biomarkers for detecting prostate cancer
JP2005526972A (ja) * 2002-05-02 2005-09-08 シファーゲン バイオシステムズ， インコーポレイテッド 多糖系ヒドロゲルをコーティングした表面を有するバイオチップ
WO2004030511A2 (en) 2002-05-10 2004-04-15 Eastern Virginia Medical School Prostate cancer biomarkers

Also Published As

Publication number Publication date
AU2006203948A1 (en) 2006-07-13
WO2006074360A2 (en) 2006-07-13
EP1838867B1 (de) 2011-03-09
EP1838867A2 (de) 2007-10-03
CA2593184A1 (en) 2006-07-13
US20080248500A1 (en) 2008-10-09
US7811772B2 (en) 2010-10-12
WO2006074360A3 (en) 2007-01-11
DE602006020544D1 (de) 2011-04-21
JP2008527351A (ja) 2008-07-24
EP1838867A4 (de) 2009-03-04

Similar Documents

Publication Publication Date Title
ATE501267T1 (de) Apolipoprotein-a-ii-isoform als biomarker für prostatakrebs
Bonne et al. Salivary biomarker development using genomic, proteomic and metabolomic approaches
Kuppusamy et al. Proteins are potent biomarkers to detect colon cancer progression
Haldrup et al. DNA methylation signatures for prediction of biochemical recurrence after radical prostatectomy of clinically localized prostate cancer
ATE490465T1 (de) Diagnose- und prognoseverfahren von blasenkrebs.
ATE373239T1 (de) Serum macrophage migration inhibitory factor (mif) als marker für prostata krebs
Kwon et al. Serpin peptidase inhibitor clade A member 1 is a biomarker of poor prognosis in gastric cancer
BRPI0720371B8 (pt) métodos para diagnóstico ou monitoramento da progressão de câncer de próstata em um indivíduo e uso in vitro de pelo menos um homeodomínio contendo o fator de transcrição como um biomarcador para câncer de próstata
WO2009019370A3 (fr) Procede de dosage de l'apolipoproteine aii pour le diagnostic in vitro du cancer colorectal
BRPI1013688A8 (pt) Proteínas de ligação de il-17.
DE602005019294D1 (de) Mrna-verhältnisse in harnsedimenten und/oder harn als prognostische und/oder theranostische marker für prostatakrebs
Leung et al. Ovarian cancer biomarkers: current state and future implications from high-throughput technologies
CY1112852T1 (el) Μεθοδος προσδιορισμου της μεθυλιωσης dνα σε δειγματα αιματος ή ουρων
ES2570632T3 (es) Procedimiento de determinación del inhibidor de elastasa de leucocito in vitro del cáncer colorrectal
RU2011106957A (ru) Онкоген nrf2 и его применение
DE602007007209D1 (de) Verwendung des proteins s100a 12 als marker für kolorektalkarzinom
DK2211180T3 (da) Anvendelse af protein SATB2 som markør til at skelne colorectal cancer fra andre former for cancer
Zergoun et al. IL-6/NOS2 inflammatory signals regulate MMP-9 and MMP-2 activity and disease outcome in nasopharyngeal carcinoma patients
ATE474228T1 (de) Reagenz für hämoglobinabbau
WO2008048508A3 (en) Prognostic biomarkers in patients with ovarian cancer
WO2007146668A3 (en) Use of imp3 as a prognostic marker for cancer
WO2010028373A3 (en) Methods for diagnosing cancer and determining the overall survival and disease-free survival of cancer patients
DE602007007958D1 (de) Antikörper gegen ein epitop auf agr2, assays und hybridome
Rostila et al. Reactive oxygen species-regulating proteins peroxiredoxin 2 and thioredoxin, and glyceraldehyde-3-phosphate dehydrogenase are differentially abundant in induced sputum from smokers with lung cancer or asbestos exposure
ATE468535T1 (de) Verwendung von nnmt als marker für lungenkrebs

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties